Down-regulation of TFF expression in gastrointestinal cell lines by cytokines and nuclear factors

Cellular Physiology and Biochemistry

Volumn 12, Issue 4, 2002, Pages 197-206

  Dossinger, Veronika ^a,b   Kayademir, Tuncay ^a   Blin, Nikolaus ^a   Gött, Peter ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

C EBP ; Gastric carcinogenesis; Inflammatory bowel disease; Interleukin 1 ; Interleukin 6; NF B; Trefoil peptides

Indexed keywords

ACUTE PHASE PROTEIN; CCAAT ENHANCER BINDING PROTEIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; NUCLEAR FACTOR; TREFOIL PEPTIDE TFF1; TREFOIL PEPTIDE TFF2; TREFOIL PEPTIDE TFF3; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CELL LINE; CELL STIMULATION; CELL STRAIN HT29; CHRONIC GASTRITIS; CONTROLLED STUDY; DOWN REGULATION; ENTERITIS; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IN VITRO STUDY; INTESTINE CELL; INTESTINE MUCOSA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; ULCER; WOUND HEALING;

LOTUS;

EID: 0036386842     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066279     Document Type: Article

References (55)

1. Thim L: Trefoil peptides: from structure to function. Cell Mol Life Sci 1997;53:888-903.
2. Sands BE, Podolsky DK: The trefoil peptide family. Annu Rev Physiol 1996;58:253-273.
3. Sommer P, Blin N, Gott P: Tracing the evolutionary origin of the TFF-domain, an ancient motif at mucous surfaces. Gene 1999;236:133-136.
4. Gott P, Beck S, Machado JC, Carneiro F, Schmitt H, Blin N: Human trefoil peptides: genomic structure in 21q22.3 and coordinated expression. Eur J Hum Genet 1996;4:308-315.
5. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P: Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988;241:705-708.
6. Tomasetto C, Rio MC, Gautier C, Wolf C, Hareuveni M, Chambon P, Lathe R: hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990;9:407-414.
7. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK: Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 1994;94:376-383.
8. Mashimo H, Wu DC, Podolsky DK, Fishman MC: Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262-265.
9. Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM: Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 1996;93:2137-2142.
10. Marchbank T, Cox HM, Goodlad RA, Giraud AS, Moss SF, Poulsom R, Wright NA, Jankowski J, Playford RJ: Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. J Biol Chem 2001;276:24088-24096.
11. Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC: Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-262.
12. Podolsky DK: Mechanisms of regulatory peptide action in the gastrointestinal tract: es. J Gastroenterol 2000;35:69-74.
13. Babyatsky MW, deBeaumont M, Thim L, Podolsky DK: Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 1996;110:489-497.
14. Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS: Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 1999;44:636-642.
15. Taupin DR, Kinoshita K, Podolsky DK: Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA 2000;97:799-804.
16. Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K: Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig Dis 1994;12:290-304.
17. Sartor RB: Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997;92:5S-11S.
18. Woywodt A, Ludwig D, Neustock P, Kruse A, Schwarting K, Jantschek G, Kirchner H, Stange EF: Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1999;11:267-276.
19. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenney JS, Baumann R, Poindron P, Duclos B: Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 1996;39:684-689.
20. Fattori E, Cappelletti M, Costa P, Sellitto C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V: Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 1994;180:1243-1250.
21. Fantuzzi G, Dinarello CA: The inflammatory response in interleukin-1 beta-deficient mice: comparison with other cytokine-related knock-out mice. J Leukoc Biol 1996;59:489-493.
22. Calnan DP, Westley BR, May FE, Floyd DN, Marchbank T, Playford RJ: The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. J Pathol 1999;188:312-317.
23. Uchino H, Kataoka H, Itoh H, Hamasuna R, Koono M: Overexpression of intestinal trefoil factor in human colon carcinoma cells reduces cellular growth in vitro and in vivo. Gastroenterology 2000;118:60-69.
24. Uchino H, Kataoka H, Itoh H, Koono M: Expression of intestinal trefoil factor mRNA is downregulated during progression of colorectal carcinomas. J Clin Pathol 1997;50:932-934.
25. Nogueira AM, Machado JC, Carneiro F, Reis CA, Gott P, Sobrinho-Simoes M: Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation. J Pathol 1999;187:541-548.
26. Luqmani Y, Bennett C, Paterson I, Corbishley CM, Rio MC, Chambon P, Ryall G: Expression of the pS2 gene in normal, benign and neoplastic human stomach. Int J Cancer 1989;44:806-812.
27. Park WS, Oh RR, Park JY, Yoo NJ, Lee SH, Shin MS, Kim SY, Kim YS, Lee JH, Kim HS, An WG, Lee JY: Mapping of a new target region of allelic loss at 21q22 in primary gastric cancers. Cancer Lett 2000;159:15-21.
28. Park WS, Oh RR, Park JY, Lee JH, Shin MS, Kim HS, Lee HK, Kim YS, Kim SY, Lee SH, Yoo NJ, Lee JY: Somatic mutations of the trefoil factor family 1 gene in gastric cancer. Gastroenterology 2000;119:691-698.
29. El Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M, Fraumeni JF, Jr., Rabkin CS: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404:398-402.
30. Yamaoka Y, Kodama T, Kita M, Imanishi J, Kashima K, Graham DY: Relation between cytokines and Helicobacter pylori in gastric cancer. Helicobacter 2001;6:116-124.
31. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
32. Schmid RM, Adler G: NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. Gastroenterology 2000;118:1208-1228.
33. Murakami S, Lefebvre V, de Crombrugghe B: Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem 2000;275:3687-3692.
34. Akira S, Hirano T, Taga T, Kishimoto T: Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J 1990;4:2860-2867.
35. Vinson CR, Sigler PB, McKnight SL: Scissors-grip model for DNA recognition by a family of leucine zipper proteins. Science 1989;246:911-916.
36. Stein B, Cogswell PC, Baldwin AS, Jr.: Functional and physical associations between NF-kappa B and C/EBP family members: a Rel domain-bZIP interaction. Mol Cell Biol 1993;13:3964-3974.
37. Begbie M, Notley C, Tinlin S, Sawyer L, Lillicrap D: The Factor VIII acute phase response requires the participation of NFkappaB and C/EBP. Thromb Haemost 2000;84:216-222.
38. Beck S, Sommer P, Blin N, Gott P: 5′-flanking motifs control cell-specific expression of trefoil factor genes (TFF). Int J Mol Med 1998;2:353-361.
39. Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck RP, Bravo R, Kelly K, Siebenlist U: A novel mitogen-inducible gene product related to p50/p105-NF-kappa B participates in transactivation through a kappa B site. Mol Cell Biol 1992;12:685-695.
40. Desbarats L, Gaubatz S, Eilers M: Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc. Genes Dev 1996;10:447-460.
41. Panja A, Goldberg S, Eckmann L, Krishen P, Mayer L: The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol 1998;161:3675-3684.
42. Familari M, Cook GA, Taupin DR, Marryatt G, Yeomans ND, Giraud AS: Trefoil peptides are early markers of gastrointestinal maturation in the rat. Int J Dev Biol 1998;42:783-789.
43. Otto WR, Patel K: Trefoil factor family (TFF)-domain peptides in the mouse: embryonic gastrointestinal expression and wounding response. Anat Embryol (Berl) 1999;199:499-508.
44. Xian CJ, Howarth GS, Mardell CE, Cool JC, Familari M, Read LC, Giraud AS: Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol 1999;277:G785-G795.
45. Kinoshita K, Taupin DR, Itoh H, Podolsky DK: Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000;20:4680-4690.
46. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, Podolsky DK: Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 1995;109:516-523.
47. Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L, Enerback S: Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer 2000;86:337-343.
48. Jobin C, Sartor RB: The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. AJP Cell Physiol 2000;278:C451-C462.
49. Fontaine V, van der ME, de Graaf J, ter Schegget J, Struyk L: A functional NF-kappaB binding site in the human papillomavirus type 16 long control region. Virology 2000;272:40-49.
50. Wissink S, van Heerde EC, Schmitz ML, Kalkhoven E, van der BB, Baeuerle PA, van der Saag PT: Distinct domains of the RelA NF-kappaB subunit are required for negative cross-talk and direct interaction with the glucocorticoid receptor. J Biol Chem 1997;272:22278-22284.
51. Supakar PC, Jung MH, Song CS, Chatterjee B, Roy AK: Nuclear factor kappa B functions as a negative regulator for the rat androgen receptor gene and NF-kappa B activity increases during the age- dependent desensitization of the liver. J Biol Chem 1995;270:837-842.
52. Segain JP, Raingeard dlB, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP: Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403.
53. Kaiser GC, Yan F, Polk DB: Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999;116:602-609.
54. Desilets A, Gheorghiu I, Yu SJ, Seidman EG, Asselin C: Inhibition by deacetylase inhibitors of IL-1-dependent induction of haptoglobin involves CCAAT/Enhancer-binding protein isoforms in intestinal epithelial cells. Biochem Biophys Res Commun 2000;276:673-679.
55. Pei DQ, Shih CH: Transcriptional activation and repression by cellular DNA-binding protein C/EBP. J Virol 1990;64:1517-1522.